ChronSeal® study completed and continuing positive results in the follow-up of the ChronVac-C®-study

ChronSeal® study completed and continuing positive results in the follow-up of
the ChronVac-C®-study

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and
the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and
Kringle have jointly decided that the results will be publicly available on May
27th.
 
At follow-up of the ChronVac-C® -study where patients now have started treatment
according to standard-of-care (interferon and ribavirin) all patients (100%)
were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of
virus/mL blood already at treatment week four. This type of rapid treatment
response is very unusual for patients infected with the hard to treat form of
HCV called genotype 1 and further underscores a role for ChronVac-C® in a
combination therapy.


The ChronVac-C®-study on patients chronically infected with hepatitis C virus
(HCV) of genotype 1 is, as has been previously reported, finalized and shows
that the therapeutic vaccine has good safety and shows positive clinical data.
Two patients in the ChronVac-C®-study have received an additional dose
approximately 6-12 months after the fourth vaccination and analysis of the
results are under way. Now six patients in the study have started treatment with
standard of care-therapy, i.e. interferon combined with ribavirin. Five of these
(83%) have responded quickly on the treatment with <50 virus copies/mL blood
already after four weeks (so called rapid viral response) in comparison to
normally only 10-15% rapid viral response after standard treatment only. This
unusually rapid reduction of virus in the blood indicates that there is a role
for ChronVac-C® in combination therapy. All six patients are now virus free and
the two patients who have already been treated for 24 weeks could at that time
stop therapy and are today considered cured. Also this good treatment outcome is
unusual for patients infected with HCV of genotype 1 where the normal treatment
time is 48 weeks and 40-50% of the patients are virus free after completing
their treatment.

“We are very happy over the results we have obtained in the ChronVac-C® study
and look forward with confidence to the results from the ChronSeal® study. An
intensive work is now ongoing with the continued clinical development. We look
forward with excitement to begin clinical studies that will take us closer to
final medicines” says Anders Vahlne, CEO of ChronTech Pharma.







For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, 
E-mail: anders.vahlne@ki.se




About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more information,
please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.